Molnupiravir (EIDD-2801) CAS 2349386-89-4 COVID-19 API Kūlana Kiʻekiʻe
Hoʻolako Kalepa Molnupiravir a me nā Intermediates pili me ke kūlana kiʻekiʻe
Uridine CAS 58-96-8
Cytidine CAS 65-46-3
Molnupiravir N-1 CAS 2346620-55-9
Molnupiravir (EIDD-2801) CAS 2349386-89-4
| Inoa Kimia | Molnupiravir (EIDD-2801) |
| Nā huaʻōlelo like | MK-4482;β-D-N4-Hydroxycytidine-5′-isopropyl ester;((2R,3S,4R,5R)-3,4-dihydroxy-5-((E)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2 -yl)methyl isobutyrate |
| Helu CAS | 2349386-89-4 |
| Helu CAT | RF-API97 |
| Kūlana Kūʻai | Ma ka waihona, ʻoi aku ka nui o ka hana a hiki i nā haneli kilogram |
| ʻĀpana Molekala | C13H19N3O7 |
| Kaumaha Molecular | 329.31 |
| Ka hikiwawe | Hiki ke hoʻoheheʻe ʻia ma DMSO |
| Brand | Kemika Ruifu |
| 'ikamu | Nā kikoʻī |
| Ka nana aku | Keʻokeʻo a hiki i ka pauda keʻokeʻo |
| ʻIkepili IR | Kūlike ʻo Sample Spectrum me ka maʻamau kuhikuhi |
| ʻIke HPLC | ʻO ka manawa paʻa o ka piko nui o ka hāpana hāpana e pili ana i ka hopena maʻamau |
| Na mea pili | |
| haumia A | ≤0.15% |
| haumia B | ≤0.15% |
| ʻO nā mea haumia ʻole i hōʻike ʻia | ≤0.15% |
| Huina paumaele i hoakaka ole ia | ≤0.30% |
| Huina paumaele | ≤0.50% |
| Nā mea hoʻoheheʻe koena | |
| N-Heptana | ≤5000ppm |
| Ethanol | ≤5000ppm |
| Isopropyl Acetate | ≤5000ppm |
| Acetonitrile | ≤410ppm |
| Methylene Dichloride | ≤600ppm |
| Acetone | ≤5000ppm |
| Isopropanol | ≤5000ppm |
| Waiwai (KF) | ≤0.50% |
| Koena ma ka Ignition | ≤0.10% |
| ʻO ka hoʻololi ʻana | -7.5° a i -9.5° (C=0.5, Methanol) |
| Nā Metala Kaumaha | ≤10ppm |
| Maʻemaʻe / Kaʻina Hanana | ≥99.5% (230nm) |
| Hana ʻIke / ʻIke | 98.0%~102.0% (HPLC ma ke kumu maloʻo) |
| Ola Pahu | 24 mahina |
| Kūlana hoʻāʻo | Kūlana ʻoihana |
| Hoʻohana | API, Molnupiravir (EIDD-2801) COVID-19 Keakea |
Pūʻolo: ʻO ka ʻōmole, ʻeke ʻeke alumini, pahu pahu pahu, 25kg / pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;Palekana mai ka malamalama, ka ma'ū a me ka pest infestation.
ʻO ka Molnupiravir (EIDD-2801, MK-4482) he prodrug bioavailable waha o ka ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931) me ka hana antiviral ākea ākea e kūʻē iā SARS-CoV-2, MERS-CoV, ʻO SARS-CoV, a me ka mea kumu kumu o COVID-19.Kūʻai ʻia ʻo Molnupiravir ma lalo o ka inoa inoa ʻo Lagevrio a ma ke ʻano he emorivir.Ua hōʻike ʻia ʻo Molnupiravir e hoʻomaikaʻi i ka hana pulmonary, hoʻemi i ke kaumaha o ke kino a hoʻemi i ka nui o ka maʻi maʻi i loko o ka māmā.Ma waho aʻe o ka hana e kūʻē i nā coronaviruses, ua hōʻike ʻo Molnupiravir, i loko o nā noiʻi noiʻi, i ka hana e kūʻē i ka maʻi maʻi kau a me ka manu, respiratory syncytial virus, chikungunya virus, Ebola virus, Venezuelan equine encephalitis virus, a me Eastern equine encephalitis virus.Ua hoʻokumu mua ʻia ʻo Molnupiravir e mālama i ka maʻi maʻi maʻi ma ke Kulanui ʻo Emory e ka hui ʻoihana lāʻau lapaʻau o ke kulanui, ʻo Drug Innovation Ventures ma Emory (DRIVE), akā ua haʻalele ʻia no nā hopohopo mutagenicity.Ua loaʻa iā ia e ka hui ʻo Miami ʻo Ridgeback Biotherapeutics, i hui pū me Merck & Co. e hoʻomohala hou i ka lāʻau.Ua ʻae ʻia ʻo Molnupiravir no ka hoʻohana olakino ma United Kingdom i Nowemapa 2021.
